SEC Form 4 · accession 0001127602-18-012796
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Francis Cogan
Director
Period of report
Mar 23, 2018
Accepted (ET)
Mar 26, 2018 · 6:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 23, 2018 | M | 5,833 | $26.615 | A | 58,452 | D | |
| Common StockF2 | Mar 23, 2018 | S | 5,833 | $75.0193 | D | 52,619 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F3 | $26.615 | Mar 23, 2018 | M | 5,833 | D | — | May 8, 2018 | Common Stock | 5,833 | 35,001 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2Sale prices reported for the transactions reported here range from $74.63 to $75.41. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F3Options vest quarterly over a period of one year from date of grant.